$-0.29 EPS Expected for Miragen Therapeutics, Inc. (MGEN)

August 9, 2018 - By Pearl Odom

Analysts expect Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report $-0.29 EPS on August, 10.They anticipate $0.05 EPS change or 14.71 % from last quarter’s $-0.34 EPS. After having $-0.18 EPS previously, Miragen Therapeutics, Inc.’s analysts see 61.11 % EPS growth. The stock decreased 7.00% or $0.44 during the last trading session, reaching $5.85. About 248,209 shares traded or 59.53% up from the average. Miragen Therapeutics, Inc. (NASDAQ:MGEN) has declined 34.18% since August 9, 2017 and is downtrending. It has underperformed by 46.75% the S&P500.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $177.51 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The company's clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Seekingalpha.com which released: “Miragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q2 2018 Results – Earnings Call Transcript” on August 08, 2018, also Benzinga.com with their article: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” published on August 07, 2018, Nasdaq.com published: “miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference” on July 31, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: Seekingalpha.com and their article: “miRagen Therapeutics and The Leukemia & Lymphoma Society inks an agreement for the development of MRG-106” published on August 06, 2018 as well as Nasdaq.com‘s news article titled: “miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018” with publication date: July 25, 2018.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.